BRN2 is a non-canonical melanoma tumor-suppressor by Hamm, M, Sohier, P, Petit, V, Sanchez-del-Campo, L, Mosteo, L, Goding, C, Et al.

Acriflavine, a potent inhibitor of HIF-1α, disturbs glucose metabolism and suppresses ATF4-protective pathways in melanoma under non-hypoxic conditions by Martí-Díaz, R, Montenegro, MF, Cabezas-Herrera, J, Goding, CR, Rodríguez-López, JN, Sánchez-del-Campo, L

Directed phenotype switching as an effective antimelanoma strategy. by Sáez-Ayala, M, Montenegro, M, Sánchez-Del-Campo, L, Fernández-Pérez, M, Chazarra, S, Freter, R, Middleton, M, Piñero-Madrona, A, Cabezas-Herrera, J, Goding, C, Rodríguez-López, J

MITF induces escape from innate immunity in melanoma by Sánchez-Del-Campo, L, Martí-Díaz, R, Montenegro, MF, González-Guerrero, R, Hernández-Caselles, T, Martínez-Barba, E, Piñero-Madrona, A, Cabezas-Herrera, J, Goding, CR, Rodríguez-López, JN

Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development. by Sacilotto, N, Monteiro, R, Fritzsche, M, Becker, P, Sanchez-Del-Campo, L, Liu, K, Pinheiro, P, Ratnayaka, I, Davies, B, Goding, C, Patient, R, Bou-Gharios, G, De Val, S

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma by Falletta, P, Sanchez-del-Campo, L, Chauhan, J, Effern, M, Kenyon, A, Kershaw, C, Siddaway, R, Lisle, R, Freter, R, Daniels, M, Lu, X, Tüting, T, Middleton, M, Buffa, F, Willis, A, Pavitt, G, Ronai, Z, Sauka-Spengler, T, Hölzel, M, Goding, C